Market Overview

Psychemedics Announces Addition Of FDA Cleared Drugs


Psychemedics Corporation (NASDAQ: PMD), hair testing pioneer and global leader for over twenty-five years, announced the addition of 2 new drugs to the company's drug testing panels. In response to growing abuse concerns, the addition of Oxymorphone was made to the synthetic opiate testing panel and D-Amphetamine/Adderall® was added as an option to the Amphetamine panel.

Raymond C. Kubacki, Chairman and CEO stated:  "Sadly, more and more prescription drugs are being abused. As the scientific leader in drug testing, we at Psychemedics continue to advance the science and use our top flight scientific team and R&D resources to develop new tests that will deter people from abusing these additional drugs."

Oxymorphone (commonly known by the brand name Opana®) is an opioid prescription pain reliever that has a high potential for abuse, is approximately two times stronger than OxyContin®, and is reported by abusers to be a replacement for Oxycodone. Oxymorphone was placed on the Drug Alert Watch by the U.S. Department of Justice in 2011, as a growing nationwide threat because of the increase in abuse and overdoses.  Psychemedics now

See full press release

Posted-In: News Press Releases


Related Articles (PMD)

View Comments and Join the Discussion!

Is SoundCloud Planning On Competing With Apple And Pandora?

Digimarc Expands Digimarc Barcode Sales Channel With Retail Solutions Provider SAM Group